231
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Terms Index

Pages 305-308 | Published online: 20 Oct 2008

Terms Index

96-well Protein Precipitation, 337

ABCB1, 327

Active metabolite, 286

Adenosine Analog, 373

Allosterism, 101, 137

Amlodipine Camsylate, 344

Analytical, 60, 70, 71, 72, 73, 75, 76, 77, 107, 133, 134, 161, 168, 175, 183, 197, 227, 229, 231, 234, 269, 291, 297, 299, 310, 348, 338, 359, 380

Animal Species, 311

Antiparasitic, 82

BCLEAR®, 239

Bile acids, 105

Bilirubin, 382

Bioactivation, 287, 306

Bioavailability, 70, 79, 80, 81, 82, 89, 135, 141, 156, 171, 172, 186, 213, 242, 343, 353, 366, 370, 372, 378, 390

Biomarkers, 60

Biotransformation, 299

Bupropion, 207

Caco-2, 238, 304

Calcein assay, 376

Cardiotoxicity, 166

Cefepime-L-carnitine interaction, 181

Children, 96

Circadian Rhythm, 65

Circadian Toxicology, 148

Citral, 207

Clearance prediction, 83, 84, 86, 87, 90, 98, 101, 144, 146, 158, 171, 188, 228, 233, 240, 243, 239, 343, 280, 326, 363

Clinical Pharmacokinetics, 160

Clozapine and 4-ethylphenol, 274

CNS penetration, 152

Conjugation reactions and enzymes, 59,89, 93, 92, 95, 96, 97, 159, 162, 201, 249, 258, 279, 291, 306, 309, 316, 334, 336, 382, 387

Constitutive Androstane Receptor, 355, 356

Cooperative effect, 109

Coumarin, 231

Covalent Binding, 257

CPM, 231

CYP2B6, 207

CYP2D6, 139

CYP2E1 X-ray structure, 140

CYP2J2, 294

CYP3A, 327

Cytochrome b5, 138

Cytochrome P450, 57, 60, 63, 64, 65, 67, 88, 99, 100, 103, 104, 105, 107, 108, 109, 111, 112, 113, 115, 118, 120, 121, 122, 123, 124, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 141, 143, 144, 145, 148, 163, 169, 180, 182, 184, 185, 186, 191, 193, 194, 195, 196, 197, 199, 200, 202, 203, 204, 205, 206, 208, 209, 211, 213, 215, 217, 219, 221, 227, 229, 230, 237, 242, 244, 246, 250, 254, 256, 259, 279, 285, 287, 289, 294, 303, 307, 310, 315, 319, 330, 332, 344, 355, 357, 374

Cytochrome P450 Reductase, 125

Cytotoxicity, 251

Dapagliflozin, 311

Dasatinib, 61

Data Analysis, 74

Data Mining, 274

Diabetic db/db mice, 143

Diastereomers, 286

Dibetes type-II, 145

Differences in metabolism (species, gender, age, diseases), 80, 120, 131, 135, 136, 142, 146, 147, 148, 151, 155, 162, 170, 181, 217, 219, 220, 223, 258, 276, 278, 279, 296, 301, 310, 320, 329, 331, 341, 353, 359

Different sterol composition, 242

Differentiation, 214

Diltiazem, 209

Direct hydrolysis, 231

Disposition, 145, 146, 153, 154, 156, 157, 171, 223, 225, 236, 240, 247, 281, 284, 290, 300, 301, 304, 312, 316, 324, 326, 346, 348, 353, 363, 366, 369, 372, 377, 381, 382, 383, 387

DMSO, 214

Drug Design, 250

Drug Discovery, 349

Drug discovery and development, 69, 71, 76, 78, 82, 85, 86, 89, 133, 134, 136, 151, 154, 158, 159, 161, 167, 170, 173, 175, 201, 223, 226, 227, 235, 243, 245, 250, 252, 258, 265, 266, 281, 283, 287, 290, 293, 300, 302, 309, 339, 345, 352

Drug interaction, 57, 63, 71, 77, 91, 98, 101, 106, 117, 130, 135, 141, 163, 169, 174, 178, 179, 183, 184, 185, 186, 187, 188, 189, 190, 192, 193, 197, 198, 199, 201, 203, 206, 211, 226, 229, 230, 317, 338, 344, 347, 355, 368, 374, 376, 379, 381, 389

Drug Metabolizing Enzymes, 214

Ellman's assay, 231

Energy Metabolism, 260

Enzyme induction, 63, 99, 104, 123, 143, 169, 183, 185, 189, 190, 191, 192, 193, 195, 196, 198, 199, 200, 202, 215, 221, 256, 320, 355, 356, 357

Enzyme inhibition/inactivation, 57, 59, 102, 103, 106, 113, 117, 125, 130, 163, 180, 182, 184, 191, 202, 203, 205, 208, 209, 211, 224, 226, 230, 237, 276, 287, 315, 320, 347, 377, 390

ePPK, 349

ETP, 231

Extrahepatic Metabolism, 80, 94, 123, 138, 141, 165, 172, 206, 212, 213, 241, 266, 338

Fialuridine, 261

FIH, 286

Flavin-containing monooxygenase, 149

Formulation, 352

Functional Assay, 367

Gene expression and regulation, 58, 59, 64, 94, 125, 143, 144, 189, 190, 191, 193, 195, 196, 215, 216, 217, 221, 244, 252, 318, 320, 324, 329, 336, 356, 357, 360, 375, 378, 389, 390

Genomics/Metabonomics/Proteomics, 67, 131, 322

Geraniol, 207

Glucuronide Conjugates, 311

GSH Adducts, 274

GSH conjugates, 173

GST, 314

Hepatocyte Nuclear Factor-4alpha, 216, 329

Hepatocytes, 63, 88, 90, 97, 121, 151, 161, 174, 185, 191, 192, 195, 196, 197, 200, 215, 221, 222, 223, 224, 239, 240, 241, 243, 247, 248, 252, 257, 260, 278, 298, 317, 336, 359, 362, 363, 365, 382, 383

Hepatotoxicity, 253

Herbal Remedies, 106

Herbal-Drug Interaction, 178

High throughput techniques, 69, 91, 114, 122, 129, 159, 166, 168, 205, 226, 227, 228, 230, 231, 238, 266, 276, 291, 293, 302, 307, 323, 347, 376

Huh7 cells, 214

Human, 283, 311

Human Serum, 286

Idiosyncratic Adverse Reaction, 325, 328

Idiosyncratic Reactions, 96

IdMOC, 241

In Silico, 83, 87, 112, 124, 180, 186, 188, 233, 234, 235, 236, 289, 363

In Vitro, 286

In vitro techniques, 84, 87, 88, 89, 90, 91, 93, 100, 101, 103, 104, 106, 107, 114, 117, 118, 125, 146, 159, 161, 174, 175, 192, 201, 208, 212, 223, 224, 225, 226, 227, 228, 230, 237, 239, 241, 243, 245, 249, 253, 263, 291, 293, 302, 309, 321, 322, 323, 331, 336, 338, 345, 346, 356, 357, 362, 363, 365, 367, 369, 375, 376, 377, 379, 380, 383, 386, 390

Incubation medium, 222

Indolealkylamine, 187

Inhibition, 207

Inhibitors of hepatitis C virus, 170

Intermediates, 234

Intestinal metabolism, 292

Irinotecan, 333

IVIVC, 158

Ketoconazole (KTZ), 216

Lafutidine, 275

LC-MS, 74, 295

LC-MS/MS, 337

Lipid Profiling, 74

Lipophilicity, 233

Liver Microsomes, 296

Marker Substrate, 231

Mass Balance, 311

Mass Spectrometry, 229

Mechanisms of xenobiotic toxicities, 59, 60, 65, 128, 132, 133, 134, 165, 189, 190, 206, 221, 224, 249, 250, 251, 252, 256, 257, 259, 261, 276, 298, 303, 308, 315, 321, 376

Metabolic Intermediate Complex, 204

Metabolic profiling, 69, 72, 91, 94, 147, 155, 168, 170, 178, 203, 222, 242, 249, 263, 266, 299, 301, 317, 258, 268, 269, 272, 275, 278, 281, 283, 284, 285, 290, 296, 297, 300, 303, 309, 310, 311

Metabolism, 57, 64, 67, 72, 73, 78, 83, 84, 85, 87, 88, 91, 92, 94, 95, 97, 98, 99, 101, 105, 107, 108, 109, 112, 117, 118, 121, 123, 125, 126, 128, 129, 130, 133, 134, 136, 137, 140, 146, 149, 151, 155, 158, 160, 161, 162, 164, 165, 168, 172, 182, 183, 184, 186, 189, 190, 203, 206, 209, 224, 225, 228, 234, 235, 243, 246, 247, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 265, 268, 269, 275, 277, 278, 280, 281, 283, 284, 285, 293, 294, 296, 297, 298, 300, 303, 304, 306, 307, 310, 311, 312, 315, 317, 318, 321, 322, 330, 331, 332, 341, 345, 353, 377, 378, 387

Metabolite Screening, 274

Mitochondria, 121, 261

Monoterpenoids, 207

MRP, 360

Multiple Ion Monitoring, 274

Mycotoxin, 123

Myeloperoxidase, 295

Nanotechnology, 348

Nevirapine, 315

Nonmem, 349

Non-P450 phase I enzymes, 85, 121, 136, 149, 165, 202, 317, 318, 319, 320, 321, 322, 338

Nuclear magnetic resonance (NMR), 297

Nucleoside Transporters, 373

Ocular, 212

Omega-3 fatty acids, 58

OP-hydrolysis, 231

Oral pharmacokinetic Prediction, 343

Organophosphonate, 231

P450 Reaction Phenotyping, 169

PBPK Modeling, 352

Permeability, 245

Pesticides, 128

Phakellistatin 13, 337

Pharmacogenetics, 67, 68, 98, 118, 182, 217, 219, 318, 322, 323, 324, 326, 329, 330, 331, 332, 334, 335, 337, 366

Pharmacokinetics, 187

Pharmacokinetics and Pharmacodynamics, 81, 82, 89, 118, 138, 152, 153, 154, 157, 167, 188, 198, 200, 228, 266, 280, 281, 290, 326, 339, 341, 342, 343, 344, 345, 346, 347, 348, 350, 359, 369, 372, 377, 386, 390

Pinoline, 139

Plasma pooling, 168

Polymorphism, 135, 139, 327

Population PK, 349

Prasugrel, 332

Pregnancy, 144

Pregnane X receptor (PXR), 216

Primate modeling, 341

Prostate Cancer Biomarker, 107

Protein Binding, 236

Q TRAP, 274

Quantitative Microdialysis, 153

Quantitative Whole-body Autoradiography, 167

Radioactivity Detection, 72

Reactive Intermediates, 159, 164, 295

Reactive Metabolites, 96, 276, 302, 308

Receptors/nuclear receptors, 63, 65, 192, 193, 196, 197, 200, 218, 244, 307, 323, 329, 354, 356, 357, 358, 360

Reproductive Toxicity, 256

Rifampin (RIF), 216

Rosiglitazone Maleate, 344

Sandwich-culture, 240

SGLT2, 311

Soman, 231

Species-volume of distribution and mean residence time normalized method, 343

Stereoselective metabolism, 188, 211, 332, 338

Steroid Receptor Coactivator-1 (SRC-1), 216

Tacrolimus, 327

Telavancin, 155

Teratogenicity, 165

Tissue Engineering Models, 88

Tissue Repair, 260

Transporters, 61, 62, 65, 68, 94, 141, 143, 144, 145, 152, 153, 157, 174, 181, 183, 195, 218, 225, 238, 240, 242, 244, 246, 247, 253, 261, 277, 304, 367, 326, 333, 338, 384, 324, 341, 353, 360, 361, 366, 368, 370, 371, 372, 374, 375, 378, 379, 380, 381, 382, 383, 386

Triple Quadrupole-linear Ion Trap Mass Spectrometry, 274

UGT1A1, 316

Vinflunine, 202

Xanthohumol, 378

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.